Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRYSALIS: Amivantamab in Advanced Non-Small Cell Lung Cancer
NCT02609776Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2016
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, open-label trial of amivantamab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Dose Limiting Toxicity, Number of Participants With Adverse Events and Serious AEs and 5 more. Started May 2016; status: active, not recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02609776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609776.